deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02426125

A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer (RANGE)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy

Sponsor: Eli Lilly and Company

Conditions Urothelial Carcinoma
Interventions Docetaxel Placebo Ramucirumab
Updated 27 times since 2017 Last updated: Aug 17, 2023 Started: Jul 13, 2015 Primary completion: Apr 21, 2017 Completion: Jul 26, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Urothelial Carcinoma, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 27 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Apr 2019 · 4 months · monthly snapshot~Apr 2019 – ~Aug 2019 · 4 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Apr 2020 · 6 months · monthly snapshot~Apr 2020 – ~Jul 2020 · 3 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshot~Sep 2022 – ~Sep 2023 · 12 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Dec 2025 · 2 months · monthly snapshot~Dec 2025 – present · 8 months · monthly snapshot

Change History

27 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE3

  2. Oct 2025 — Dec 2025 [monthly]

    Completed PHASE3

  3. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE3

  4. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

▶ Show 22 earlier versions

  1. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE3

  2. Sep 2022 — Sep 2023 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. Feb 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE3

  5. Apr 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  6. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE3

  7. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  8. Jul 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE3

  9. Apr 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  10. Oct 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

  11. Aug 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE3

  12. Apr 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE3

  13. Dec 2018 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  14. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE3

  15. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  16. Aug 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  17. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  18. Jun 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  19. May 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  20. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE3

  21. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  22. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Aguascalientes, Mexico , Amsterdam, Netherlands , Ankara, Turkey (Türkiye) , Antalya, Turkey (Türkiye) , Arezzo, Italy , Arnhem, Netherlands , Athens, Greece , Aurora, United States , Badajoz, Spain and 126 more locations